Operating Cash Flow CAGR:7.63%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Operating Cash Flow CAGR averages 0.21% over 3 years and 7.25% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash West Pharmaceutical Services, Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
WST Operating Cash Flow CAGR Chart
West Pharmaceutical Services, Inc. (WST)
WST Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
WST Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $653.40M | $754.80M | +$101.40M | +15.52% | +15.52% |
| 2024 | $776.50M | $653.40M | $-123.10M | -15.85% | -15.85% |
| 2023 | $724.00M | $776.50M | +$52.50M | +7.25% | +7.25% |
| 2022 | $584.00M | $724.00M | +$140.00M | +23.97% | +23.97% |
| 2021 | $472.50M | $584.00M | +$111.50M | +23.60% | +23.60% |
| 2020 | $367.20M | $472.50M | +$105.30M | +28.68% | +28.68% |
| 2019 | $288.60M | $367.20M | +$78.60M | +27.23% | +27.23% |
| 2018 | $263.30M | $288.60M | +$25.30M | +9.61% | +9.61% |
| 2017 | $219.40M | $263.30M | +$43.90M | +20.01% | +20.01% |
| 2016 | $212.40M | $219.40M | +$7.00M | +3.30% | +3.30% |
| 2015 | $182.90M | $212.40M | +$29.50M | +16.13% | +16.13% |
| 2014 | $220.50M | $182.90M | $-37.60M | -17.05% | -17.05% |
| 2013 | $187.40M | $220.50M | +$33.10M | +17.66% | +17.66% |
| 2012 | $130.70M | $187.40M | +$56.70M | +43.38% | +43.38% |
| 2011 | $138.30M | $130.70M | $-7.60M | -5.50% | -5.50% |
| 2010 | $137.70M | $138.30M | +$600.00K | +0.44% | +0.44% |
| 2009 | $135.00M | $137.70M | +$2.70M | +2.00% | +2.00% |
| 2008 | $129.20M | $135.00M | +$5.80M | +4.49% | +4.49% |
| 2007 | $143.80M | $129.20M | $-14.60M | -10.15% | -10.15% |
| 2006 | $85.60M | $143.80M | +$58.20M | +67.99% | +67.99% |
| 2005 | $68.90M | $85.60M | +$16.70M | +24.24% | +24.24% |
| 2004 | $69.20M | $68.90M | $-300.00K | -0.43% | -0.43% |
| 2003 | $53.90M | $69.20M | +$15.30M | +28.39% | +28.39% |
| 2002 | $32.70M | $53.90M | +$21.20M | +64.83% | +64.83% |
| 2001 | $48.60M | $32.70M | $-15.90M | -32.72% | -32.72% |
| 2000 | $69.40M | $48.60M | $-20.80M | -29.97% | -29.97% |
| 1999 | $71.00M | $69.40M | $-1.60M | -2.25% | -2.25% |
| 1998 | $67.70M | $71.00M | +$3.30M | +4.87% | +4.87% |
| 1997 | $63.40M | $67.70M | +$4.30M | +6.78% | +6.78% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $89.90M | -64.2% | -30.5% |
| Q4 2025 | $251.10M | +27.3% | +32.1% |
| Q3 2025 | $197.20M | +11.3% | +9.5% |
| Q2 2025 | $177.10M | +36.9% | +7.3% |
| Q1 2025 | $129.40M | -31.9% | +9.5% |
| Q4 2024 | $190.10M | +5.6% | -20.5% |
| Q3 2024 | $180.10M | +9.2% | -21.7% |
| Q2 2024 | $165.00M | +39.6% | -2.5% |
| Q1 2024 | $118.20M | -50.6% | -14.4% |
| Q4 2023 | $239.10M | +3.9% | +3.6% |
| Q3 2023 | $230.10M | +36.0% | +36.2% |
| Q2 2023 | $169.20M | +22.5% | -2.3% |
| Q1 2023 | $138.10M | -40.2% | -8.7% |
| Q4 2022 | $230.80M | +36.6% | +43.5% |
| Q3 2022 | $168.90M | -2.4% | -11.2% |
| Q2 2022 | $173.10M | +14.5% | +19.9% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green